Genetic Technologies signs multi-year distribution agreement for COVID Risk Test

Genetic Technologies is pleased to announce a co-exclusive production and distribution rights and license agreement with US-based Infinity Biologic for the production, distribution and sale of the Company's COVID-19 Serious Disease Risk Test in the United States. Highlights: Initial three-year co-exclusive licence agreement between IBX and GTG for the production, distribution, sales and marketing of GTG's COVID-19 Risk Test in the US, under the 'powered by GeneType' branding; IBX is required to make minimum payments to GTG totaling US$2.9 million over the term to maintain exclusivity with an initial upfront payment of US$50k followed by minimum payments totaling US$850k in the first year and US$1.0 million in each of the second and third years; IBX may terminate this agreement at any time and for any reason upon 60 days written notice to GTG with effect upon the expiry of the 60-day period; IBX currently has the capacity to process over 100,000 COVID-19 Risk Tests per day across its two major labs and is well-positioned with an existing network of SARS-CoV-2 testing partners and associated medical practitioners across the US to be able to use GTG's COVID-19 Risk Test in conjunction with these existing third-party SARS-CoV-2 Tests; Underlying royalty structure is on a per unit basis of US$10; IBX will define and decide the sales and end-to-consumer pricing structure for the COVID-19 Risk Test.